In Silico臨床試驗市場規模、佔有率和成長分析（按部署模式、試驗階段、應用、治療領域、最終用戶和地區分類）：產業預測（2026-2033 年）

2024 年全球In Silico臨床試驗市場價值為 42 億美元，預計到 2025 年將成長至 44.9 億美元，到 2033 年將成長至 76.6 億美元，預測期（2026-2033 年）複合年成長率為 6.9%。

In Silico模擬臨床試驗市場的主要驅動力來自計算建模技術的進步、監管機構認可度的提高以及降低藥物研發成本和縮短研發週期的迫切需求。電腦In Silico試驗利用電腦模擬數位雙胞胎技術，提高了藥物安全性和有效性的預測準確性，成為傳統方法的替代和補充手段。這種創新方法降低了病患風險，加快了核准流程，並有助於在受試者招募困難的弱勢群體中進行研究。隨著運算能力和機器學習技術的進步，以及從基礎藥物動力學建模到高階多尺度模擬的不斷發展，相關人員對預測模型的信心日益增強。隨著人工智慧進一步變革患者建模和試驗最佳化，該市場有望蓬勃發展，為包括醫療設備製造和腫瘤學在內的各個領域創造眾多機會。

全球In Silico臨床試驗市場促進因素

全球In Silico臨床試驗市場的主要促進因素之一是對經濟高效的藥物研發流程日益成長的需求。In Silico試驗利用先進的計算模型和模擬技術來預測新療法的療效和安全性，從而顯著減少傳統臨床試驗所需的時間和資源。此外，遵守嚴格的監管要求以及對個人化醫療的需求也進一步推動了In Silico試驗的應用。這些因素共同作用，正在改變臨床研究的進行方式，促進創新，並減輕醫療保健系統的負擔。

全球In Silico臨床試驗市場的限制因素

全球In Silico臨床試驗市場的主要限制因素之一是監管機構對計算模型和模擬的接受程度存在不確定性。隨著技術的不斷發展，制定相關指南和標準可能會有所滯後，這反過來又會導致製藥公司和研究機構在In Silico試驗全面整合到開發平臺中時猶豫不決。此外，相關人員在投入資源採用這種創新方法之前，會要求獲得充分的檢驗和證據，因此，對計算預測的準確性和可靠性的擔憂也會阻礙其更廣泛的應用。

全球In Silico臨床試驗市場趨勢

全球In Silico臨床試驗市場正經歷著向人工智慧主導的個人化模擬的變革性轉變，這主要得益於尖端機器學習和機制建模技術的應用。這項變革使得創造能夠體現不同生理和疾病路徑特徵的個人化虛擬患者成為可能，從而促進自適應方案的設計。隨著相關人員越來越重視反映患者異質性的模型，識別早期可能產生療效的患者和無療效的患者的能力，不僅簡化了試驗流程，還提高了生物標記選擇和給藥策略的預測準確性。這一趨勢減少了成本高昂的試驗迭代次數，同時提高了轉換可靠性，並提升了藥物發現和開發各個階段決策的整體效率。

目錄

介紹

• 分析目的
• 市場定義和範圍

分析方法

• 分析過程
• 二級資料和一級資料的方法
• 估算市場規模的方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場觀察

• 主要成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 市場魅力指數（2025）
• PESTLE分析
• 監理情勢

全球In Silico臨床試驗市場規模：依部署模式分類

• 基於雲端的平台
• 本地部署平台
• 混合平台

全球In Silico臨床試驗市場規模：依試驗階段分類

• 臨床前試驗
• I期試驗
• II期試驗
• III期試驗
• 第四期臨床試驗/上市後監測

全球In Silico臨床試驗市場規模：按應用領域分類

• 藥物研發
• 醫療設備開發
• 個人化醫療
• 疾病建模
• 毒性測試
• 臨床試驗的最佳化
• 向監管機構申請並檢驗

全球In Silico臨床試驗市場規模：依治療領域分類

• 瘤
• 心血管疾病
• 神經病學
• 感染疾病
• 代謝性疾病
• 呼吸系統疾病
• 整形外科
• 罕見疾病
• 其他

全球In Silico臨床試驗市場規模：依最終用戶分類

• 製藥公司
• 生技公司
• 醫療設備製造商
• CRO（委外研發機構）
• 學術研究機構
• 其他

全球In Silico臨床試驗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭格局

• 前五大公司對比
• 主要公司的市場定位（2025 年）
• 主要公司採取的策略
• 近期市場趨勢
• 主要公司市佔率（2025 年）
• 主要公司簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要公司簡介

• Dassault Systemes
• Ansys
• Simulations Plus
• Certara
• Insilico Medicine
• InSilicoTrials Technologies
• Aetion
• Physiomics
• Novadiscovery
• Rosa & Co. LLC
• Immunetrics
• Genedata
• ELEM Biotech
• Applied Biomath
• Biomax Informatics
• HeartFlow
• Numerate
• Cyclica
• Evotec
• Qure.ai

結論與建議

Global In Silico Clinical Trials Market size was valued at USD 4.2 Billion in 2024 and is poised to grow from USD 4.49 Billion in 2025 to USD 7.66 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The in silico clinical trials market is primarily fueled by advances in computational modeling, increasing regulatory acceptance, and the urgent need to minimize drug development costs and timelines. By employing computer simulations and digital twins, in silico trials enhance predictions of safety and efficacy, serving as both alternative and complementary approaches to traditional methods. This innovative approach reduces patient risk, expedites approvals, and facilitates studies within hard-to-recruit vulnerable populations. With the ongoing evolution from basic pharmacokinetic modeling to sophisticated multiscale simulations, supported by improved computational power and machine learning, industry stakeholders are witnessing greater confidence in predictive models. As AI further transforms patient representation and trial optimization, the market is set to thrive, presenting numerous opportunities across various sectors, including device manufacturing and oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Silico Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global In Silico Clinical Trials Market Segments Analysis

Global in silico clinical trials market is segmented by deployment model, trial phase, application, therapeutic area, end user and region. Based on deployment model, the market is segmented into Cloud-Based Platforms, On-Premises Platforms and Hybrid Platforms. Based on trial phase, the market is segmented into Preclinical Trials, Phase I Trials, Phase II Trials, Phase III Trials and Phase IV / Post-Market Studies. Based on application, the market is segmented into Drug Development, Medical Device Development, Personalized Medicine, Disease Modeling, Toxicology Testing, Clinical Trial Optimization and Regulatory Submission & Validation. Based on therapeutic area, the market is segmented into Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Metabolic Disorders, Respiratory Diseases, Orthopedics, Rare Diseases and Others. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations (CROs), Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global In Silico Clinical Trials Market

One of the key market drivers for the global in silico clinical trials market is the increasing demand for cost-effective and efficient drug development processes. In silico trials leverage advanced computational models and simulations to predict the effectiveness and safety of new therapeutics, significantly reducing the time and resources spent on traditional clinical trials. Additionally, the pressure to comply with stringent regulatory requirements and the need for personalized medicine approaches further propel the popularity of in silico trials. These factors collectively contribute to a transformative shift in how clinical research is conducted, enhancing innovation and reducing the burden on healthcare systems.

Restraints in the Global In Silico Clinical Trials Market

One of the key market restraints for the global in silico clinical trials market is the regulatory uncertainty surrounding the acceptance of computational models and simulations by regulatory agencies. As the technology evolves, there may be a lag in the establishment of guidelines and standards that govern its use, leading to hesitancy among pharmaceutical companies and research institutions to fully integrate in silico trials into their development pipelines. Additionally, concerns regarding the accuracy and reliability of computational predictions can hinder broader adoption, as stakeholders demand substantial validation and evidence before committing resources to this innovative approach.

Market Trends of the Global In Silico Clinical Trials Market

The Global In Silico Clinical Trials market is witnessing a transformative shift towards AI-driven personalized simulations, propelled by the adoption of cutting-edge machine learning and mechanistic modeling techniques. This evolution enables the creation of individualized virtual patients that embody a range of physiological and disease pathways, fostering adaptive protocol design. As stakeholders increasingly prioritize models that reflect patient heterogeneity, the ability to identify likely responders and nonresponders early on not only streamlines trial processes but also enhances predictive accuracy for biomarker selection and dosing strategies. This trend is reducing the need for costly trial iterations while bolstering translational confidence and improving overall decision-making efficiency across various stages of drug development.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global In Silico Clinical Trials Market Size by Deployment Model & CAGR (2026-2033)

• Market Overview
• Cloud-Based Platforms
• On-Premises Platforms
• Hybrid Platforms

Global In Silico Clinical Trials Market Size by Trial Phase & CAGR (2026-2033)

• Market Overview
• Preclinical Trials
• Phase I Trials
• Phase II Trials
• Phase III Trials
• Phase IV / Post-Market Studies

Global In Silico Clinical Trials Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Development
• Medical Device Development
• Personalized Medicine
• Disease Modeling
• Toxicology Testing
• Clinical Trial Optimization
• Regulatory Submission & Validation

Global In Silico Clinical Trials Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Metabolic Disorders
• Respiratory Diseases
• Orthopedics
• Rare Diseases
• Others

Global In Silico Clinical Trials Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Manufacturers
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others

Global In Silico Clinical Trials Market Size & CAGR (2026-2033)

• North America (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • US
  • Canada
• Europe (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Dassault Systemes
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ansys
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Simulations Plus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSilicoTrials Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aetion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Physiomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novadiscovery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rosa & Co.\ LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunetrics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genedata
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ELEM Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Applied Biomath
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Informatics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HeartFlow
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numerate
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyclica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qure.ai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations